Next Article in Journal
Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical Framework
Next Article in Special Issue
Gender, Albuminuria and Chronic Kidney Disease Progression in Treated Diabetic Kidney Disease
Previous Article in Journal
Research Insights on Neural Effects of Auditory Deprivation and Restoration in Unilateral Hearing Loss: A Systematic Review
Previous Article in Special Issue
Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients
Editorial

Special Issue “Diabetic Nephropathy: Diagnosis, Prevention and Treatment”

1
Molecular and Cellular Biology in Renal and Vascular Pathology, IIS-Fundación Jiménez Díaz-UniversidadAutónoma Madrid, 28040 Madrid, Spain
2
Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, 28029 Madrid, Spain
3
Division of Nephrology, School of Medicine, Universidad Austral de Chile, 5090000 Valdivia, Chile
4
Vascular and Renal Translational Research Group. Institut de Recerca Biomèdica de Lleida (IRBLleida), 25198 Lleida, Spain
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(3), 813; https://doi.org/10.3390/jcm9030813
Received: 11 March 2020 / Accepted: 13 March 2020 / Published: 17 March 2020
(This article belongs to the Special Issue Diabetic Nephropathy: Diagnosis, Prevention and Treatment)
Diabetic nephropathy (DN) is the main cause of end-stage renal disease. DN is a complex disease mediated by genetic and environmental factors, and many cellular and molecular mechanisms are involved in renal damage in diabetes. There are no biomarkers that reflect the severity of the underlying renal histopathological changes and can effectively predict the progression of renal damage and stratify the risk of DN among individuals with diabetes mellitus. Current therapeutic strategies are based on the strict control of glucose and blood pressure levels and, although there are new anti-diabetic drugs, these treatments only retard renal damage progression, being necessary novel therapies. In this Special Issue, there are several comprehensive reviews and interesting original papers covering all these topics, which would be of interest to the growing number of readers of the Journal of Clinical Medicine. View Full-Text
Keywords: chronic kidney disease; diabetic nephropathy; biomarkers; treatment chronic kidney disease; diabetic nephropathy; biomarkers; treatment
MDPI and ACS Style

Ruiz-Ortega, M.; Rodrigues-Diez, R.R.; Lavoz, C.; Rayego-Mateos, S. Special Issue “Diabetic Nephropathy: Diagnosis, Prevention and Treatment”. J. Clin. Med. 2020, 9, 813. https://doi.org/10.3390/jcm9030813

AMA Style

Ruiz-Ortega M, Rodrigues-Diez RR, Lavoz C, Rayego-Mateos S. Special Issue “Diabetic Nephropathy: Diagnosis, Prevention and Treatment”. Journal of Clinical Medicine. 2020; 9(3):813. https://doi.org/10.3390/jcm9030813

Chicago/Turabian Style

Ruiz-Ortega, Marta, Raul R. Rodrigues-Diez, Carolina Lavoz, and Sandra Rayego-Mateos. 2020. "Special Issue “Diabetic Nephropathy: Diagnosis, Prevention and Treatment”" Journal of Clinical Medicine 9, no. 3: 813. https://doi.org/10.3390/jcm9030813

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop